新型脂肪因子在多囊卵巢综合征中的研究进展
Research Progress of Novel Adipokines in Polycystic Ovary Syndrome
DOI: 10.12677/acm.2025.153715, PDF,   
作者: 顾雯方*, 陈梦晴, 张 锐：黑龙江中医药大学研究生院，黑龙江 哈尔滨；匡洪影#：黑龙江中医药大学附属第一医院妇科二科，黑龙江 哈尔滨
关键词: 多囊卵巢综合征；脂肪因子；Metrnl；Chemerin；Apelin；胰岛素抵抗；Polycystic Ovary Syndrome； Adipokines； Metrnl； Chemerin； Apelin； Insulin Resistance
摘要: 多囊卵巢综合征(Polycystic Ovary Syndrome, PCOS)是育龄期女性最常见的生殖内分泌疾病之一，全球发病率约为15%~20%。其核心特征包括高雄激素血症、排卵障碍、卵巢多囊样改变，常伴随胰岛素抵抗(Insulin Resistance, IR)、肥胖及糖脂代谢紊乱。脂肪组织分泌的脂肪因子(Adipokines)作为重要的信号分子，在调控糖脂代谢和卵巢微环境中发挥关键作用。近年来，Metrnl、Chemerin、Apelin、Vaspin等新型脂肪因子的发现为解析PCOS异质性提供了新视角。文章聚焦上述因子，梳理其作用机制、临床关联及研究进展，以期为PCOS的临床诊疗提供新思路。
Abstract: Polycystic Ovarian Syndrome (PCOS) is one of the most common reproductive endocrine diseases in women of childbearing age, with a global incidence of about 15% to 20%. Its core features include hyperandrogenism, ovulation disorder, and polycystic ovarian changes, which are often accompanied by Insulin Resistance (IR), obesity, and disorder of glucose and lipid metabolism. Adipokines secreted by adipose tissue, as an important signal molecule, play a key role in regulating glucose and lipid metabolism and the ovarian microenvironment. In recent years, the discovery of new fat factors such as Metrnl, Chemerin, Apelin, and Vaspin provides a new perspective for analyzing PCOS heterogeneity. This paper focuses on the above factors and combs their mechanism of action, clinical relevance, and research progress in order to provide new ideas for clinical diagnosis and treatment of PCOS.
文章引用：顾雯方, 陈梦晴, 张锐, 匡洪影. 新型脂肪因子在多囊卵巢综合征中的研究进展[J]. 临床医学进展, 2025, 15(3): 1084-1090. https://doi.org/10.12677/acm.2025.153715

参考文献

[1] Sirmans, S. and Pate, K. (2013) Epidemiology, Diagnosis, and Management of Polycystic Ovary Syndrome. Clinical Epidemiology, 6, 1-13. [Google Scholar] [CrossRef] [PubMed]
[2] Xu, Y., Zhu, H., Li, W., Chen, D., Xu, Y., Xu, A., et al. (2022) Targeting Adipokines in Polycystic Ovary Syndrome and Related Metabolic Disorders: From Experimental Insights to Clinical Studies. Pharmacology & Therapeutics, 240, Article 108284. [Google Scholar] [CrossRef] [PubMed]
[3] Ter Horst, K.W., van Galen, K.A., Gilijamse, P.W., Hartstra, A.V., de Groot, P.F., van der Valk, F.M., et al. (2017) Methods for Quantifying Adipose Tissue Insulin Resistance in Overweight/obese Humans. International Journal of Obesity, 41, 1288-1294. [Google Scholar] [CrossRef] [PubMed]
[4] Dhawan, D. and Sharma, S. (2020) Abdominal Obesity, Adipokines and Non-Communicable Diseases. The Journal of Steroid Biochemistry and Molecular Biology, 203, Article 105737. [Google Scholar] [CrossRef] [PubMed]
[5] Kim, H.W., Shi, H., Winkler, M.A., Lee, R. and Weintraub, N.L. (2020) Perivascular Adipose Tissue and Vascular Perturbation/Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 2569-2576. [Google Scholar] [CrossRef] [PubMed]
[6] Zheng, S., Li, Z., Song, J., Liu, J. and Miao, C. (2016) Metrnl: A Secreted Protein with New Emerging Functions. Acta Pharmacologica Sinica, 37, 571-579. [Google Scholar] [CrossRef] [PubMed]
[7] Ushach, I., Burkhardt, A.M., Martinez, C., Hevezi, P.A., Gerber, P.A., Buhren, B.A., et al. (2015) METEORIN-Like Is a Cytokine Associated with Barrier Tissues and Alternatively Activated Macrophages. Clinical Immunology, 156, 119-127. [Google Scholar] [CrossRef] [PubMed]
[8] 任小胖, 郝婉姣, 刘梅云, 等. METRNL在PCOS患者血清中的表达及意义[J]. 生殖医学杂志, 2023, 32(9): 1342-1347.
[9] Wang, C., Pan, Y., Song, J., Sun, Y., Li, H., Chen, L., et al. (2019) Serum METRNL Level Is Correlated with Insulin Resistance, but Not with β-Cell Function in Type 2 Diabetics. Medical Science Monitor, 25, 8968-8974.
[10] Du, Y., Ye, X., Lu, A., Zhao, D., Liu, J., Cheng, J., et al. (2020) Inverse Relationship between Serum METRNL Levels and Visceral Fat Obesity (VFO) in Patients with Type 2 Diabetes. Diabetes Research and Clinical Practice, 161, Article 108068. [Google Scholar] [CrossRef] [PubMed]
[11] Li, Z., Song, J., Zheng, S., Fan, M., Guan, Y., Qu, Y., et al. (2015) Adipocyte METRNL Antagonizes Insulin Resistance through PPARγ Signaling. Diabetes, 64, 4011-4022. [Google Scholar] [CrossRef] [PubMed]
[12] Lee, J.O., Byun, W.S., Kang, M.J., Han, J.A., Moon, J., Shin, M., et al. (2020) The Myokine Meteorin-Like (METRNL) Improves Glucose Tolerance in Both Skeletal Muscle Cells and Mice by Targeting AMPKα2. The FEBS Journal, 287, 2087-2104. [Google Scholar] [CrossRef] [PubMed]
[13] Li, Z., Zheng, S., Wang, P., Xu, T., Guan, Y., Zhang, Y., et al. (2014) Subfatin Is a Novel Adipokine and Unlike Meteorin in Adipose and Brain Expression. CNS Neuroscience & Therapeutics, 20, 344-354. [Google Scholar] [CrossRef] [PubMed]
[14] Rao, R.R., Long, J.Z., White, J.P., Svensson, K.J., Lou, J., Lokurkar, I., et al. (2014) Meteorin-Like Is a Hormone that Regulates Immune-Adipose Interactions to Increase Beige Fat Thermogenesis. Cell, 157, 1279-1291. [Google Scholar] [CrossRef] [PubMed]
[15] Fouani, F.Z., Fadaei, R., Moradi, N., Zandieh, Z., Ansaripour, S., Yekaninejad, M.S., et al. (2020) Circulating Levels of Meteorin-Like Protein in Polycystic Ovary Syndrome: A Case-Control Study. PLOS ONE, 15, e0231943. [Google Scholar] [CrossRef] [PubMed]
[16] Jung, T.W., Lee, S.H., Kim, H., Bang, J.S., Abd El-Aty, A.M., Hacımüftüoğlu, A., et al. (2018) METRNL Attenuates Lipid-Induced Inflammation and Insulin Resistance via AMPK or PPARδ-Dependent Pathways in Skeletal Muscle of Mice. Experimental & Molecular Medicine, 50, 1-11. [Google Scholar] [CrossRef] [PubMed]
[17] 陈佩佩. 镍纹样蛋白与多囊卵巢综合征胰岛素抵抗和体外受精-胚胎移植结局的相关性研究[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2022.
[18] Nagpal, S., Patel, S., Jacobe, H., DiSepio, D., Ghosn, C., Malhotra, M., et al. (1997) Tazarotene-Induced Gene 2 (TIG2), a Novel Retinoid-Responsive Gene in Skin. Journal of Investigative Dermatology, 109, 91-95. [Google Scholar] [CrossRef] [PubMed]
[19] Rourke, J.L., Dranse, H.J. and Sinal, C.J. (2012) Towards an Integrative Approach to Understanding the Role of Chemerin in Human Health and Disease. Obesity Reviews, 14, 245-262. [Google Scholar] [CrossRef] [PubMed]
[20] Yang, S., Wang, Q., Huang, W., Song, Y., Feng, G., Zhou, L., et al. (2015) Are Serum Chemerin Levels Different between Obese and Non-Obese Polycystic Ovary Syndrome Women? Gynecological Endocrinology, 32, 38-41. [Google Scholar] [CrossRef] [PubMed]
[21] Tan, B.K., Chen, J., Farhatullah, S., Adya, R., Kaur, J., Heutling, D., et al. (2009) Insulin and Metformin Regulate Circulating and Adipose Tissue Chemerin. Diabetes, 58, 1971-1977. [Google Scholar] [CrossRef] [PubMed]
[22] Li, X., Zhu, Q., Wang, W., Qi, J., He, Y., Wang, Y., et al. (2019) Elevated Chemerin Induces Insulin Resistance in Human Granulosa-Lutein Cells from Polycystic Ovary Syndrome Patients. The FASEB Journal, 33, 11303-11313. [Google Scholar] [CrossRef] [PubMed]
[23] Bose, C., Mukherjee, B., Mukherjee, A., Pramanik, S., Saha, C., Mondal, A., et al. (2024) Serum Chemerin Levels Correlate with Severity of Dysglycemia in Young Adult Women with Polycystic Ovary Syndrome. Journal of the Endocrine Society, 8, bvae023. [Google Scholar] [CrossRef] [PubMed]
[24] Reverchon, M., Cornuau, M., Rame, C., Guerif, F., Royere, D. and Dupont, J. (2012) Chemerin Inhibits Igf-1-Induced Progesterone and Estradiol Secretion in Human Granulosa Cells. Human Reproduction, 27, 1790-1800. [Google Scholar] [CrossRef] [PubMed]
[25] Kim, J.Y., Xue, K., Cao, M., Wang, Q., Liu, J., Leader, A., et al. (2013) Chemerin Suppresses Ovarian Follicular Development and Its Potential Involvement in Follicular Arrest in Rats Treated Chronically with Dihydrotestosterone. Endocrinology, 154, 2912-2923. [Google Scholar] [CrossRef] [PubMed]
[26] Estienne, A., Mellouk, N., Bongrani, A., Plotton, I., Langer, I., Ramé, C., et al. (2021) Involvement of Chemerin and CMKLR1 in the Progesterone Decrease by PCOS Granulosa Cells. Reproduction, 162, 427-436. [Google Scholar] [CrossRef] [PubMed]
[27] Bongrani, A., Plotton, I., Mellouk, N., Ramé, C., Guerif, F., Froment, P., et al. (2022) High Androgen Concentrations in Follicular Fluid of Polycystic Ovary Syndrome Women. Reproductive Biology and Endocrinology, 20, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[28] Lima, P.D.A., Nivet, A., Wang, Q., Chen, Y., Leader, A., Cheung, A., et al. (2018) Polycystic Ovary Syndrome: Possible Involvement of Androgen-Induced, Chemerin-Mediated Ovarian Recruitment of Monocytes/Macrophages. Biology of Reproduction, 99, 838-852. [Google Scholar] [CrossRef] [PubMed]
[29] Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M., et al. (1998) Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor. Biochemical and Biophysical Research Communications, 251, 471-476. [Google Scholar] [CrossRef] [PubMed]
[30] Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigné, C., Mazzucotelli, A., et al. (2005) Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology, 146, 1764-1771. [Google Scholar] [CrossRef] [PubMed]
[31] Kawamata, Y., Habata, Y., Fukusumi, S., Hosoya, M., Fujii, R., Hinuma, S., et al. (2001) Molecular Properties of Apelin: Tissue Distribution and Receptor Binding. Biochimica et Biophysica Acta—Molecular Cell Research, 1538, 162-171. [Google Scholar] [CrossRef] [PubMed]
[32] Liu, J., Liu, M. and Chen, L. (2017) Novel Pathogenesis: Regulation of Apoptosis by Apelin/APJ System. Acta Biochimica et Biophysica Sinica, 49, 471-478. [Google Scholar] [CrossRef] [PubMed]
[33] Castan-Laurell, I., Masri, B. and Valet, P. (2019) The Apelin/APJ System as a Therapeutic Target in Metabolic Diseases. Expert Opinion on Therapeutic Targets, 23, 215-225. [Google Scholar] [CrossRef] [PubMed]
[34] Yue, P., Jin, H., Aillaud, M., Deng, A.C., Azuma, J., Asagami, T., et al. (2010) Apelin Is Necessary for the Maintenance of Insulin Sensitivity. American Journal of Physiology-Endocrinology and Metabolism, 298, E59-E67. [Google Scholar] [CrossRef] [PubMed]
[35] Gören, K., Sağsöz, N., Noyan, V., Yücel, A., Cağlayan, O. and Bostancı, M.S. (2012) Plasma Apelin Levels in Patients with Polycystic Ovary Syndrome. Journal of the Turkish German Gynecological Association, 13, 27-31.
[36] 杜静, 张二红, 廖月婵, 等. 多囊卵巢综合征患者血清Apelin水平与激素、代谢异常的关系[J]. 中国妇幼保健, 2018, 33(5): 1048-1050.
[37] Liu, Q., Jiang, J., Shi, Y., Mo, Z. and Li, M. (2020) Apelin/Apelin Receptor: A New Therapeutic Target in Polycystic Ovary Syndrome. Life Sciences, 260, Article 118310. [Google Scholar] [CrossRef] [PubMed]
[38] 蔡玉, 刁海丹. 血清TGF-β1、Apelin、CYP19Al水平与PCOS内分泌异常间的关系分析[J]. 生殖医学杂志, 2022, 31(4): 463-467.
[39] Chang, C., Tsai, Y., Lee, C., Chan, T., Wang, S. and Su, J. (2011) Lower Serum Apelin Levels in Women with Polycystic Ovary Syndrome. Fertility and Sterility, 95, 2520-2523.e2. [Google Scholar] [CrossRef] [PubMed]
[40] Bongrani, A., Mellouk, N., Rame, C., Cornuau, M., Guérif, F., Froment, P., et al. (2019) Ovarian Expression of Adipokines in Polycystic Ovary Syndrome: A Role for Chemerin, Omentin, and Apelin in Follicular Growth Arrest and Ovulatory Dysfunction? International Journal of Molecular Sciences, 20, Article 3778. [Google Scholar] [CrossRef] [PubMed]
[41] Shirasuna, K., Shimizu, T., Sayama, K., Asahi, T., Sasaki, M., Berisha, B., et al. (2008) Expression and Localization of Apelin and Its Receptor APJ in the Bovine Corpus Luteum during the Estrous Cycle and Prostaglandin F2-Induced Luteolysis. Reproduction, 135, 519-525. [Google Scholar] [CrossRef] [PubMed]
[42] Roche, J., Rame, C., Reverchon, M., Mellouk, N., Cornuau, M., Guerif, F., et al. (2016) Apelin (APLN) and Apelin Receptor (APLNR) in Human Ovary: Expression, Signaling, and Regulation of Steroidogenesis in Primary Human Luteinized Granulosa Cells. Biology of Reproduction, 95, 104-104. [Google Scholar] [CrossRef] [PubMed]
[43] Hida, K., Wada, J., Eguchi, J., Zhang, H., Baba, M., Seida, A., et al. (2005) Visceral Adipose Tissue-Derived Serine Protease Inhibitor: A Unique Insulin-Sensitizing Adipocytokine in Obesity. Proceedings of the National Academy of Sciences, 102, 10610-10615. [Google Scholar] [CrossRef] [PubMed]
[44] Zhou, X., Chen, Y., Tao, Y., Zhang, W., Xu, W. and Lu, X. (2019) Serum Vaspin as a Predictor of Adverse Cardiac Events in Acute Myocardial Infarction. Journal of the American Heart Association, 8, Article 13542. [Google Scholar] [CrossRef] [PubMed]
[45] Tan, B.K., Heutling, D., Chen, J., Farhatullah, S., Adya, R., Keay, S.D., et al. (2008) Metformin Decreases the Adipokine Vaspin in Overweight Women with Polycystic Ovary Syndrome Concomitant with Improvement in Insulin Sensitivity and a Decrease in Insulin Resistance. Diabetes, 57, 1501-1507. [Google Scholar] [CrossRef] [PubMed]
[46] 李文君, 宋玉良, 程贤鹦. 多囊卵巢综合征患者血清Vaspin水平及与胰岛素抵抗的相关性分析[J]. 中国现代医学杂志, 2020, 30(2): 72-75.
[47] Koiou, E., Tziomalos, K., Dinas, K., Katsikis, I., Kalaitzakis, E., Delkos, D., et al. (2011) The Effect of Weight Loss and Treatment with Metformin on Serum Vaspin Levels in Women with Polycystic Ovary Syndrome. Endocrine Journal, 58, 237-246. [Google Scholar] [CrossRef] [PubMed]
[48] Liu, S., Duan, R., Wu, Y., Du, F., Zhang, J., Li, X., et al. (2018) Effects of Vaspin on Insulin Resistance in Rats and Underlying Mechanisms. Scientific Reports, 8, Article No. 13542. [Google Scholar] [CrossRef] [PubMed]
[49] Heiker, J.T., Klöting, N., Kovacs, P., Kuettner, E.B., Sträter, N., Schultz, S., et al. (2013) Vaspin Inhibits Kallikrein 7 by Serpin Mechanism. Cellular and Molecular Life Sciences, 70, 2569-2583. [Google Scholar] [CrossRef] [PubMed]

为你推荐